Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients.
Clinical observations revealed an increased prevalence of iron deficiency anemia without chronic bleeding in patients treated with serial low-density lipoprotein (LDL) apheresis. Since several different proteins are adsorbed by LDL apheresis beside pro-atherogenic lipoproteins, we examined the modification of the full blood count, plasma iron, vitamin B12, folic acid, and hemolysis by LDL apheresis. Nineteen patients (55 (50-59) years, 4 female, 15 male) undergoing chronic LDL apheresis due to mixed dyslipidemia (N = 17), homozygous familiar hypercholesterolemia (N = 1) or isolated elevated lipoprotein(a) (N = 1) were included in this study. They were treated with direct adsorption of lipoproteins (DALI; N = 6), heparin-induced LDL-precipitation (HELP; N = 7) or double filtration plasmapheresis (DFPP; N = 6). The patients' full blood count, iron metabolism (plasma iron, ferritin, transferrin, transferrin saturation), vitamins involved in erythropoiesis (vitamin B12 and folic acid), and markers of hemolysis (haptoglobin and free hemoglobin) were analyzed directly before and after LDL apheresis. A single LDL apheresis session significantly decreased the levels (reduction in the median [25(th)-75(th) percentiles] of: ferritin 9.8 [1.3-18] %; P = 0.004), transferrin (12.1 [10.0-15.96] %; P = 0.0005), and vitamin B12 (17.8 [16.2-20.8] %; P = 0.0005). Thereby, transferrin and vitamin B12 were decreased in all (N = 19) and ferritin in 74% (N = 14) of the patients. Twelve out of 19 patients (63.2%) had mild anemia despite iron administration in 14 out of 19 patients (73.7%). LDL apheresis had no significant influence on full blood count, plasma iron, transferrin saturation, folic acid, or hemolysis. Similar changes were observed in all LDL apheresis methods used. LDL apheresis significantly decreases ferritin, transferrin, and vitamin B12, suggesting an influence of serial LDL apheresis on erythropoiesis.
Bramlage
Carsten P
CP
Department of Medicine, Nephrology and Rheumatology, Georg-August-University Göttingen, Göttingen, Germany.
Armstrong
Victor W
VW
Zapf
Antonia
A
Bramlage
Peter
P
Mueller
Gerhard A
GA
Koziolek
Michael J
MJ
D000740:Anemia / Q000209:etiology*; D001781:Blood Component Removal / Q000009:adverse effects* / Q000379:methods; D050171:Dyslipidemias / Q000628:therapy*; D004920:Erythropoiesis; D005260:Female; D005293:Ferritins / Q000378:metabolism; D005374:Filtration; D006493:Heparin / Q000737:chemistry; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000628:therapy; D017270:Lipoprotein(a) / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis / Q000379:methods; D014168:Transferrin / Q000378:metabolism; D014805:Vitamin B 12 / Q000378:metabolism
D017270:Lipoprotein(a); D008077:Lipoproteins, LDL; D014168:Transferrin; D006493:Heparin; D005293:Ferritins; D014805:Vitamin B 12